HERON THERAPEUTICS, INC. /DE/ 8-K

What Happened

• Heron Therapeutics announced on June 2, 2026 (8-K filing) that the U.S. District Court for the District of Delaware issued a decision on June 1, 2026 finding the asserted claims of Heron’s U.S. Patent Nos. 12,115,255 and 12,290,520 (covering CINVANTI®) are invalid.
• The matter arose after Slayback Pharma (now owned by Azurity) submitted an NDA and Heron sued for patent infringement; the case proceeded to a two-day bench trial focused on Azurity’s §112 defenses. Post-trial briefing finished February 6, 2026 and closing arguments were held March 24, 2026.
• Heron said it intends to appeal the decision to the United States Court of Appeals for the Federal Circuit and noted the ruling does not affect prior settlement agreements related to CINVANTI (aprepitant) injectable emulsion or APONVIE®.

Key Details

• Court decision date: June 1, 2026; 8-K filed June 2, 2026.
• Patents held invalid: U.S. Patent No. 12,115,255 and U.S. Patent No. 12,290,520 (claims asserted at trial).
• Case history highlights: Paragraph IV notice received Dec 11, 2023; initial complaint filed Jan 24, 2024; trial commenced Nov 17, 2025; post-trial briefing completed Feb 6, 2026.
• Company action: Heron intends to appeal to the Federal Circuit and may seek a stay of market entry (forward-looking; subject to risks).

Why It Matters

• For investors, the court ruling removes two asserted patent barriers protecting Heron’s CINVANTI product, which could affect market exclusivity and competitive dynamics if not stayed or reversed on appeal.
• The appeal to the Federal Circuit is the next legal step; outcomes there and any decision on a stay will materially influence Heron’s revenue prospects related to CINVANTI.
• The company emphasizes the decision does not change existing settlement agreements for CINVANTI or APONVIE®, but the litigation outcome bears directly on potential generic competition timing.